Skip to main content
OpenTrials

Clinical trial condition

Myelodysplastic Syndrome With Excess Blasts-2

Explore clinical trials studying Myelodysplastic Syndrome With Excess Blasts-2. Study availability and eligibility vary by location and protocol.

8 public trials 2 recruiting studies
Refine in advanced search Browse all conditions

Myelodysplastic Syndrome With Excess Blasts-2 trial results

Recruiting

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT03850574

Conditions
Bone Marrow Diseases, Chronic Disease, Chronic Myelomonocytic Leukemia, +16 more
Locations
  • The Kirklin Clinic of UAB Hospital Birmingham, Alabama, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • University of California Irvine Irvine, California, United States
  • UCSD Moores Cancer Center La Jolla, California, United States
View all 34 locations
View Trial Details
Completed

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD

NCT02220985

Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, +57 more
Locations
  • University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States
  • Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
View Trial Details
Active, Not Recruiting

Hu8F4 in Treating Patients With Advanced Hematologic Malignancies

NCT02530034

Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blast Crisis, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, +31 more
Locations
  • Augusta University Augusta, Georgia, United States
  • Montefiore Medical Center, Albert Einstein College of Medicine The Bronx, New York, United States
  • M D Anderson Cancer Center Houston, Texas, United States
  • Huntsman Cancer Institute Salt Lake City, Utah, United States
View Trial Details
Active, Not Recruiting

A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

NCT04027309

Conditions
Acute Myeloid Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +6 more
Locations
  • AU-Adelaide-FLINDERS Adelaide, Australia
  • AU-Adelaide-RAH Adelaide, Australia
  • AU-Brisbane-PAH Brisbane, Australia
  • AU-Brisbane-RBWH Brisbane, Australia
View all 193 locations
View Trial Details
Active, Not Recruiting

A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy

NCT03839771

Conditions
Acute Myeloid Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +6 more
Locations
  • AU-Adelaide-FLINDERS Adelaide, Australia
  • AU-Adelaide-RAH Adelaide, Australia
  • AU-Brisbane-PAH Brisbane, Australia
  • AU-Camperdown-RPA Camperdown, Australia
View all 181 locations
View Trial Details

Related conditions